207 related articles for article (PubMed ID: 14580255)
1. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.
Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E
Breast Cancer Res; 2003; 5(6):R199-205. PubMed ID: 14580255
[TBL] [Abstract][Full Text] [Related]
2. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose.
Moadel RM; Weldon RH; Katz EB; Lu P; Mani J; Stahl M; Blaufox MD; Pestell RG; Charron MJ; Dadachova E
Cancer Res; 2005 Feb; 65(3):698-702. PubMed ID: 15705862
[TBL] [Abstract][Full Text] [Related]
3. Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy.
Mortimer JE; Taylor ME
Breast Cancer Res; 2003; 5(6):329-31. PubMed ID: 14580251
[TBL] [Abstract][Full Text] [Related]
4. Experimental study on the therapeutic effect of positron emission tomography agent [¹⁸F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model.
Fang S; Wang J; Jiang H; Zhang Y; Xi W; Zhao C; Tian M; Zhang H
Cancer Biother Radiopharm; 2010 Dec; 25(6):733-40. PubMed ID: 21204768
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapeutic use of 2-deoxy-2-[18F]fluoro-D-glucose--a comment.
Meyer MA
Breast Cancer Res; 2004; 6(1):E2. PubMed ID: 14680488
[No Abstract] [Full Text] [Related]
6. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
7. Metabolic fate of 18F-FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma.
Kaarstad K; Bender D; Bentzen L; Munk OL; Keiding S
J Nucl Med; 2002 Jul; 43(7):940-7. PubMed ID: 12097467
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
9. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
10. Effective radiotherapy of primary tumors and metastasis with 18F-2-deoxy-2-fluoro-D-glucose in C57BL/6 mice.
Caridad V; Arsenak M; Abad MJ; Martín R; Guillén N; Colmenter LF; Taylor P
Cancer Biother Radiopharm; 2008 Jun; 23(3):371-5. PubMed ID: 18593370
[TBL] [Abstract][Full Text] [Related]
11. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
13. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
14. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
[TBL] [Abstract][Full Text] [Related]
15. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth.
Dadachova E; Nguyen A; Lin EY; Gnatovskiy L; Lu P; Pollard JW
Nucl Med Biol; 2005 Oct; 32(7):695-700. PubMed ID: 16243644
[TBL] [Abstract][Full Text] [Related]
16. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
[TBL] [Abstract][Full Text] [Related]
17. Monitoring Mitochondrial Complex-I Activity Using Novel PET Probe 18F-BCPP-EF Allows Early Detection of Radiotherapy Effect in Murine Squamous Cell Carcinoma.
Murayama C; Kawaguchi AT; Kamijo A; Naito K; Kanazawa M; Tsukada H
PLoS One; 2017; 12(1):e0170911. PubMed ID: 28125711
[TBL] [Abstract][Full Text] [Related]
18. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake.
Kubota R; Kubota K; Yamada S; Tada M; Ido T; Tamahashi N
J Nucl Med; 1994 Jan; 35(1):104-12. PubMed ID: 8271030
[TBL] [Abstract][Full Text] [Related]
19. [Clinical experience with positron emission tomography with 2-fluorine, 18F-2-deoxy-d-glucose used for the diagnosis of malignant breast neoplasms].
Tiutin L; Fadeev N; Ryzhkova D; Kostenikiv N; Arzumanov A; Savello V; Tlostanova M
Vestn Rentgenol Radiol; 2001; (6):14-8. PubMed ID: 11858029
[TBL] [Abstract][Full Text] [Related]
20. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.
Lapointe D; Brasseur N; Cadorette J; La Madeleine C; Rodrigue S; van Lier JE; Lecomte R
J Nucl Med; 1999 May; 40(5):876-82. PubMed ID: 10319764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
